WallStSmart

Alcon AG (ALC)vsFemasys Inc (FEMY)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Alcon AG generates 472220% more annual revenue ($10.86B vs $2.30M). ALC leads profitability with a 5.9% profit margin vs 0.0%. ALC earns a higher WallStSmart Score of 51/100 (C-).

ALC

Buy

51

out of 100

Grade: C-

Growth: 4.7Profit: 4.5Value: 3.3Quality: 6.8
Piotroski: 3/9

FEMY

Avoid

16

out of 100

Grade: F

Growth: 5.3Profit: 2.5Value: 5.0Quality: 4.5
Piotroski: 3/9Altman Z: -11.43
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ALCSignificantly Overvalued (-22.0%)

Margin of Safety

-22.0%

Fair Value

$65.08

Current Price

$66.03

$0.95 premium

UndervaluedFair: $65.08Overvalued

Intrinsic value data unavailable for FEMY.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ALC2 strengths · Avg: 9.5/10
Price/BookValuation
1.5x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.259/10

Conservative balance sheet, low leverage

FEMY1 strengths · Avg: 8.0/10
Price/BookValuation
2.1x8/10

Reasonable price relative to book value

Areas to Watch

ALC4 concerns · Avg: 2.8/10
Return on EquityProfitability
3.8%3/10

ROE of 3.8% — below average capital efficiency

Profit MarginProfitability
5.9%3/10

5.9% margin — thin

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

P/E RatioValuation
53.8x2/10

Premium valuation, high expectations priced in

FEMY4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$27.30M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Debt/EquityHealth
1.193/10

Elevated debt levels

Comparative Analysis Report

WallStSmart Research

Bull Case : ALC

The strongest argument for ALC centers on Price/Book, Debt/Equity. PEG of 1.27 suggests the stock is reasonably priced for its growth.

Bull Case : FEMY

The strongest argument for FEMY centers on Price/Book.

Bear Case : ALC

The primary concerns for ALC are Return on Equity, Profit Margin, Piotroski F-Score. A P/E of 53.8x leaves little room for execution misses.

Bear Case : FEMY

The primary concerns for FEMY are EPS Growth, Market Cap, Profit Margin.

Key Dynamics to Monitor

ALC carries more volatility with a beta of 0.70 — expect wider price swings.

ALC is growing revenue faster at 8.7% — sustainability is the question.

ALC generates stronger free cash flow (414M), providing more financial flexibility.

Monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

ALC scores higher overall (51/100 vs 16/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Alcon AG

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Alcon, Inc., an eye care company, researches, develops, manufactures, distributes and sells eye care products for eye care professionals and their patients around the world. The company is headquartered in Geneva, Switzerland.

Visit Website →

Femasys Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Femasys Inc. is a pioneering medical technology company focused on revolutionizing women's healthcare with its proprietary, non-surgical solutions for diagnosing and treating gynecological conditions, including uterine fibroids and contraception. By addressing significant unmet needs in women's health, Femasys is positioned to benefit from the growing demand for minimally invasive treatments, which enhance patient outcomes and improve healthcare efficiency. The company's innovative approach aims to set new standards of care, reinforcing its commitment to transforming the landscape of women's health and solidifying its role as a key player in this vital and expanding market.

Want to dig deeper into these stocks?